首页 > 抗体蛋白 > 抗体
APC anti-mouse CD279 (PD-1) Antibody
产品名称:
APC anti-mouse CD279 (PD-1) Antibody
产品类别:
抗体
产品编号:
135209
产品应用:
135209
[价格]
规格 价格 库存
25µg ¥ 1356 1

产品详情

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
PD-1 cDNA followed by PD-1-Ig fusion protein
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with APC under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.25 ?g per million cells in 100 ?l volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Red Laser (633 nm)
Application Notes

Additional reported applications (for the relevant formats) include: immunohistochemical staining of acetone-fixed frozen tissue3, in vivo blocking of PD-1 binding to its ligands2,3, and spatial biology (IBEX)5,6.

Application References

(PubMed link indicates BioLegend citation)
  1. Good-Jacobson KL, et al. 2010. Nat. Immunol. 11:535. (FC) PubMed
  2. Lázár-Molnár E, et al. 2008. Proc. Natl. Acad. Sci. USA 105:2658. (Block)
  3. Liang SC, et al. 2003. Eur. J. Immunol. 33:2706. (FC, IHC, Block)
  4. Tobias J, et al. 2020. Front Immunol. 11:895 (FC, ELISA) PubMed
  5. Radtke?AJ,?et al.?2020.?Proc Natl Acad Sci U S A.?117:33455-65. (SB)?PubMed
  6. Radtke?AJ,?et al.?2022.?Nat Protoc.?17:378-401. (SB)?PubMed
Product Citations
  1. Wu J et al. 2017. Immunity. 47(6):1114-1128 . PubMed
  2. Saha D et al. 2017. Cancer cell. 32(2):253-267 . PubMed
  3. Xie A et al. 2017. Endocrinology. 158(10):3140-3151 . PubMed
  4. Zhou J, et al. 2019. Immunity. 50:403. PubMed
  5. Qi Z, et al. 2022. Nat Commun. 13:182. PubMed
  6. Wu Q, et al. 2021. Cancer Commun (Lond). Online ahead of prin. PubMed
  7. Lino AC et al. 2018. Immunity. 49(1):120-133 . PubMed
  8. Wang J, et al. 2019. Front Immunol. 9:3157. PubMed
  9. Liu QZ, et al. 2018. Front Immunol. 1.131944444. PubMed
  10. Smith T, et al. 2014. J Immunol. 193:3409. PubMed
  11. Waide ML, et al. 2020. Cell Rep. 33:108503. PubMed
  12. Almshayakhchi R, et al. 2021. Front Oncol. 11:636977. PubMed
  13. Stokes J, et al. 2020. Oncoimmunology. 9:1758011. PubMed
  14. Wei JL, et al. 2021. J Immunother Cancer. 9: . PubMed
  15. Len-Letelier RA, et al. 2020. Frontiers in Immunology. 11:583382. PubMed
  16. Stewart JM, et al. 2020. ACS Biomater Sci Eng. 6:5941. PubMed
  17. Cha SE, et al. 2021. Oncoimmunology. 10:1899469. PubMed
  18. Lasso P, et al. 2020. Front Immunol. 584959:11. PubMed
  19. Imani J, et al. 2021. JCI Insight. 6:. PubMed
  20. Cheng B, et al. 2022. Cancer Commun (Lond). 42:17. PubMed
  21. Habib S, et al. 2018. Infect Immun. 86:e00019. PubMed
  22. Ren Y, et al. 2022. J Immunother Cancer. 10:. PubMed
  23. Pilones KA, et al. 2020. Cancer Immunol Res. 8:1054. PubMed
  24. LaFleur MW, et al. 2019. Nat Commun. 10:1668. PubMed
  25. Shen M, et al. 2022. Nat Cancer. 3:60. PubMed
  26. Webb ER, et al. 2022. iScience. 25:104995. PubMed
  27. Koikawa K, et al. 2021. Cell. 184(18):4753-4771.e27. PubMed
  28. Moon S, et al. 2021. J Exp Med. 218:. PubMed
  29. Shiozawa S, et al. 2022. iScience. 25:103537. PubMed
  30. Mandal RK, et al. 2021. Cell Reports. 35(6):109094. PubMed
  31. Gong N, et al. 2020. Nat Nanotechnol. 1.35625. PubMed
  32. Onishi M, et al. 2015. J Immunol. 194:2673. PubMed
  33. Wedekind MF, et al. 2021. iScience. 24(7):102759. PubMed
  34. Montalban-Arques A, et al. 2021. Cell Host Microbe. :. PubMed
  35. Si J, et al. 2020. Cancer Cell. 38(4):551-566.e11. PubMed
  36. Zheng Y, et al. 2022. J Immunol. 208:501. PubMed
  37. Molina MS, et al. 2021. Front Immunol. 12:699128. PubMed
  38. Di Pilato M, et al. 2021. Cell. 184(17):4512-4530.e22. PubMed
  39. Shimba A et al. 2018. Immunity. 48(2):286-298 . PubMed
  40. Wagner AK, et al. 2022. iScience. 25:105137. PubMed
  41. Simoni L, et al. 2020. Cell Rep. 33:108330. PubMed
  42. Charlton J, et al. 2015. PLoS One. 10:119200. PubMed
  43. Li M, et al. 2020. J Immunother Cancer. 8:00. PubMed
  44. Yang FM, et al. 2022. Front Immunol. 13:918241. PubMed
RRID
AB_2251944 (BioLegend Cat. No. 135209) AB_2159183 (BioLegend Cat. No. 135210)

Antigen Details

Structure
A 50-55 kD glycoprotein belonging to the CD28 family of the Ig superfamily.
Distribution

Induced on splenic T and B lymphocytes, thymocytes, and myeloid cells after stimulation.

Function
Involved in lymphocyte clonal selection and peripheral tolerance, prolonged survival of allografts.
Ligand/Receptor
B7-H1 (PD-L1) and B7-DC (PD-L2)
Cell Type
B cells, T cells
Biology Area
Cancer Biomarkers, Immunology, Inhibitory Molecules
Molecular Family
CD Molecules, Immune Checkpoint Receptors
Antigen References

1. Nishimura H, et al. 2001. Science 291:319
2. Agata Y, et al. 1996. Int. Immunol. 8:765
3. Liang SC, et al. 2003. Eur. J. Immunol. 33:2706
4. Barber DL, et al. 2006. Nature 439:682
5. Keir ME, et al. 2005. J. Immunol. 175:7372
6. Koehn BH. et al. 2008. J Immunol. 181:5313

Gene ID
18566 View all products for this Gene ID
UniProt
View information about CD279 on UniProt.org

联系我们

TEL:021-34661275  点击拨打热线